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test was performed. During GH therapy, 
growth velocity increased in all three pa­
tients and bone age advanced, but not as 
fast as the body height. After GH therapy, 
predicted adult height was in patient 1 
higher, in patient 2 and 3 less than calcu­
lated before treatment (Table 1). None of 
the three children in our study has devel­
oped signs of acromegaly, glucose intoler­
ance or hypertension. The Crohn disease 
activity index has not changed during the 
time of GH treatment.
There are only a few studies on GH re­
placement therapy in patients with Crohn 
disease. In 1974 McCaffery et al. [6] 
treated three adolescent patients with 
Crohn disease with human GH for a 6- 
month period and did not observe any ef­
fect on their height velocity. In 1985 Red­
mond et al. [8] also treated four patients 
with Crohn disease with human GH in a 
very small dosage (up to 6 I.U. three times 
a week). There was a definite increase in 
the growth rate in one of the patients. Fol­
low up of the other patients was pending,
Part of the effect of GH therapy in our 
patients may have been caused by the on­
set of puberty. On the other hand, the at­
tained body height is higher than expected. 
When a child is slowed he seldom 
achieves adult stature [1]. Besides, the 
catch-up growth depends on the length of 
time for which growth has been slowed 
[7]. Hence, when there is a decision for 
GH therapy in children with Crohn disease 
and growth failure, this therapy should not 
be started too late.
References
L Acheson RM (1960) Effects of nutrition 
and disease on human growth. Symp 
Soc Hum Biol 3:73
2. Hildebrand H, Karlberg J, Kristiansson 
B (1994) Longitudinal growth in chil­
dren and adolescents with inflammatory 
bowel disease. J Pediatr Gastroenterol
Nutr 18:165-173
3. Kanof ME, Lake AM, Bay less TM 
(1988) Decreased height velocity in 
children and adolescents before the di­
agnosis of Crohn’s disease. Gastroen­
terology 95:1523-1527
4.Kirschner BS (1990) Growth and devel­
opment in chronic inflammatory bowel 
disease. Acta Paediatr Scand 366:98-
104
5. Markowitz J, Grancher K, Rosa J, Aiges
H, Daum F (1993) Growth failure in pe­
diatric inflammatory bowel disease. J 
Pediatr Gastroenterol Nutr 16:373-380
6 . McCaffery TD, Nasr K, Lawrence AM, 
Kirsner JB (1974) Effect of adminis­
tered human growth hormone on growth 
retardation in inflammatory bowel dis­
ease. Dig Dis 19:411-416
7.Prader A, Tanner JM, Hamack GA von 
(1963) Catch-up growth following ill­
ness or starvation, J Pediatr 62:646-659
8. Redmond GP, Wylie R, Michener WM 
(1985) Endocrine therapy in adolescents 
with Crohn’s disease. J Adolesc Health 
Care 6 :345
9. Tanner JM (1962) Growth at adoles­
cence, 2nd edn. Blackwell, Oxford
J. Henker (13)
University of Technology Dresden, 
Department of Paediatrics,
Fetscherstrasse 74,
D-01307 Dresden, Germany 
Tel.: 0351/4583449 
Fax: 0351/4417217
R. J. van Lemmen  
B. A. Semmekrot
Muscle rigidity
causing life-threatening
hypercapnia
following fentanyl
administration
in a premature infant
Received: 10 October 1995 
Accepted: 5 November 1996
Sir: We recently treated a 32-week-prema­
ture infant boy, birth weight 1460 g, with 
mechanical ventilation because of a 
Giedion stage III respiratory distress syn­
drome, Because of agitation with decreas­
ing transcutaneous oxygen saturation, mi­
dazolam (Dormicum) was administered in­
travenously (i.v.), first at a dose of 0.1 mg/ 
kg per hour, then increased to 0.2 mg/kg 
per hour because of persisting agitation 
and hypercapnia (pC02 8-9 kPa). For rea­
sons of still insufficient sedation, fenta­
nyl i.v. was started 2 h later at a dose of
3 ¡J-g/kg per hour. In the subsequent 3 h his 
condition deteriorated: F i0 2 had to be in­
creased from 50% to 100% and severe hy­
percapnia developed (pC 02 22 kPa). The 
boy, now totally sedated, showed a gener­
alised muscle rigidity with only minimal 
chest wall excursions. Respiratory minute 
volume had dropped from ± 0,40 to 0.06
1/min and increased only slightly to 0.08 
1/min after increasing insufflation pressure 
from 18 to 24 mbar. Fentanyl was stopped
4 h after it had been started. After the 
main causes of respiratory deterioration 
had been excluded, nalaxone (0.015 mg/kg
i.v.) was given 5 h after the fentanyl infu­
sion had been stopped. There was an in­
stantaneous reaction. The respiration am­
plitudes on the monitor screen returned 
immediately, as did chest wall excursions 
and spontaneous movements. Within 1 
min F i0 2 decreased to 60% and transcuta­
neous pC 02 to 9.9 kPa. Mechanical venti­
lation could then be weaned easily, fol­
lowed by extubation on the 8 th day of 
life.
We conclude that our patient suffered 
from muscle rigidity as a si de-effect of 
opioid use. This phenomenon has so far 
only twice been described in premature in­
fants, by Huet et al. in 1992 [1] and Lajar- 
rige et al. in 1993 [2] after a 1 jig/kg per 
hour fentanyl maintenance infusion and
3 |Hg/kg bolus dose, respectively.
Opioids are commonly used in neona­
tal intensive care units for sedation and 
analgesia. However, serious ventilation 
problems may occur with their use, the 
importance of which we want to stress. If 
so, naloxone should be administered intra­
venously to antagonise the opioid effects. 
Earlier recognition would have shortened 
the delay in our patient and reduced the 
time of exposure to severe hypercapnia. 
The immediate response to naloxone sug­
gests a phenomenon induced at the opioid 
receptor site. Whether the magnitude of 
this phenomenon is dose-dependent is not 
certain but unlikely, since in all reported 
cases symptoms occurred very shortly af­
ter the administration of only moderate 
doses of fentanyl.
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